Precision Optics Corporation, Inc. (POCI) Stock Analysis
Precision Optics is transforming from a capital-constrained engineering shop into a scalable medical and aerospace optics manufacturer with improving margins, fresh liquidity, and significant re-rating potential.
Overview
Precision Optics has reached a major commercial inflection point, with Q3 FY2026 revenue up 108% year over year to a record $8.71 million and Adjusted EBITDA turning positive. A $10.63 million oversubscribed equity raise removed historical liquidity concerns, strengthened cash to $10.68 million, and positioned the company to fund high-volume medical and aerospace production ramps. With FY2026 revenue guidance implying 52%–62% growth and analyst coverage initiating at Buy, POCI is entering an institutional re-rating phase.